Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 13/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15340922 | 0.85 | PDE1C (0.41) | PDE4APDE4BPDE4CPDE4DBRD4 | |
| SCHEMBL29769081 | 0.79 | PDE1C (0.48) | PDE4BPDE4DBRD4PDE1CCREBBP | |
| SCHEMBL19868691 | 0.78 | PDE1C (0.45) | PDE4APDE4BPDE4CPDE4DBRD4 | |
| SCHEMBL15345090 | 0.77 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DBRD4 | |
| SCHEMBL23152346 | 0.76 | PDE1C (0.49) | PDE4BPDE4DPDE1CCREBBPKDM1A | |
| Hydrochloric Acid SCHEMBL31638109 | 0.74 | PDE1C (0.47) | PDE4BPDE4DBRD4PDE1CCREBBP | |
| SCHEMBL15317630 | 0.74 | QDPR (0.50) | BRD4PDE1CCREBBPKDM1AHDAC4 | |
| SCHEMBL1365601 | 0.74 | PDE1C (0.44) | PDE4BPDE4DBRD4PDE1CCREBBP | |
| SCHEMBL21876110 | 0.73 | PDE1C (0.44) | PDE4BPDE4DBRD4PDE1CCREBBP | |
| SCHEMBL21876109 | 0.73 | PDE1C (0.44) | PDE4BPDE4DBRD4PDE1CCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | PDE4A 2857/4885PDE4B 2486/4885PDE4C 2318/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PDE4A 1972/4885PDE4B 1222/4885PDE4C 1516/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PDE4A 1972/4885PDE4B 1222/4885PDE4C 1516/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | PDE4A 2857/4885PDE4B 2486/4885PDE4C 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.